Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + BEAM for R/R DLBCL ASCT
NCT06652139Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of selinexor in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Progression Free Survival at 2 years. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06652139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06652139.